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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416 A275(r¼.20). Baseline KOOS4 scores were also related to all 5 year KOOS
subscores (all outcomes p<0.01, r¼.23 to r¼.29) (Table 1).
Conclusions: Cartilage injury at baseline was related to worse patient
reported 5 year outcome. Baseline subchondral fracture and meniscus
injury were not related to 5 year outcome, however, receiving medial
meniscus surgerywas related toworse pain,QOL andkneeconﬁdence at 5
year follow-up. In comparison, lateralmeniscus surgerywasnot related to
5 year outcome. Undergoing ACLR (early or delayed) was associated with
more knee symptoms at 5 years and treatment with rehabilitation alone
resulted in worse knee conﬁdence. More joint pain, symptoms, poorer
physical function and worse QOL in the acute phase of ACL injury, were
related to worse 5 year outcome, irrespective of intervention.
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MICRORNA-33A REGULATES CHOLESTEROL SYNTHESIS AND
CHOLESTEROL EFFLUX RELATED GENES IN OSTEOARTHRITIC
CHONDROCYTES
F. Kostopoulou y, K.N. Malizos z, I. Papathanasiou y, A. Tsezou y. yDept. of
Cytogenetics and Molecular Genetics, Univ. of Thessaly, Larissa, Greece;
zDept. of Orthopaedics, Univ. of Thessaly, Larissa, Greece
Purpose: Several studies have shown that osteoarthritis (OA) is strongly
associated to metabolic related disorders, highlighting OA as the ﬁfth
component of the Metabolic Syndrome (MetS). Based on our previous
ﬁndings on dysregulation of cholesterol homeostasis in OA, we were
prompted to investigate whether microRNA-33a (miR-33a), one of the
master regulators of cholesterol and fatty acid metabolism, plays a key
role in osteoarthritis' pathogenesis.
Methods: Articular cartilage samples were obtained from 14 patients
with primary osteoarthritis undergoing total knee replacement surgery.
Normal cartilage was obtained from 9 individuals undergoing fracture
repair surgery with no history of joint disease. Bioinformatics was used
to identify miR-33a target genes. MiR-33a and Sterol Regulatory Ele-
ment Binding Protein 2 (SREBP-2) expression levels were investigated
using real-time PCR and their expression was also assessed after
treatment with Transforming Growth Factor-beta (TGF-beta) in cul-
tured chondrocytes. Investigation of Akt phosphorylation after treat-
ment with both TGF-beta and miR-33a inhibitor was assessed by
western blot analysis. Furthermore, we evaluated the effect of miR-33amimic and miR-33a inhibitor on cholesterol efﬂux related genes, ATP-
binding-cassette transporter A1 (ABCA1), Apolipoprotein A1 (ApoA1),
liver X receptors (LXRalpha and LXRbeta), as well as on matrix metal-
loproteinase-13 (MMP-13) using real time PCR assay.
Results: We found that the expression of miR-33a and its host gene
SREBP-2 were signiﬁcantly elevated in OA chondrocytes compared to
normal. We also showed that treatment of cultured chondrocytes with
TGF-beta resulted in increased expression of both miR-33a and SREBP-
2, while the TGF-beta-induced Akt phosphorylation was suppressed by
inhibition of miR-33a. Moreover, we demonstrated that treatment of
normal chondrocytes with miR-33a resulted in ABCA1 and ApoA1 sig-
niﬁcantly reduced mRNA expression levels and signiﬁcantly elevated
MMP-13 expression levels, promoting the OA phenotype, while miR-
33a's suppressive effect was reversed using its inhibitor.
Conclusions: Our ﬁndings suggest, for the ﬁrst time to our knowledge,
that miR-33a regulates cholesterol synthesis through the TGF-beta/Akt/
SREBP-2 pathway, and cholesterol efﬂux related genes ABCA1 and
ApoA1 in OA chondrocytes, pointing to its identiﬁcation as a novel
target for ameliorating the OA phenotype.
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THE ROLE OF MICRORNA-140 IN OSTEOARTHRITIS
T. Karlsen y,z, G. de Souza z, J. Brinchmann y,z. yNorwegian Center for
Stem Cell Research, Oslo, Norway; zDept. of Immunology, Oslo Univ.
Hosp., Oslo, Norway
Purpose: The purpose of this study was to determine the role of
microRNA-140 in an in vitro model of osteoarthritis (OA).
Methods: Human articular chondrocytes (ACs) and synovial ﬁbroblasts
(SFs) were isolated from patients undergoing total knee replacement
and anterior cruciate ligament surgery, respectively. Addition of
recombinant IL1B to cell cultures was used as an in vitro model of OA.
All patients provided written, informed consent. Electroporation was
used to overexpress microRNA-140. Real-time PCR was used to quantify
mRNA levels and genome-scale proteome quantiﬁcationwas performed
using mass spectrometry. ELISA and western blotting were used to
validate results from the proteome analysis.
Results: IL1B-stimulation of ACs resulted in upregulation and down-
regulation of 200 and 160 proteins, respectively. The upregulated pro-
teins included several pro-inﬂammatorymolecules such as IL1B, IL6, IL8
and the matrix degradation molecules MMP3 and MMP13. All these
proteins are known to be involved in the pathogenesis of OA.
When microRNA-140 was overexpressed in IL1B-stimulated ACs 100
and 90 proteins were downregulated and upregulated, respectively. The
downregulated proteins included IL1B, IL6, IL8, proteins involved in NF-
kappaB signaling and other proteins that are associated with OA.
However, MMP3 and MMP13 were not affected. ACAN, CSGALNACT1
(involved in chondroitin sulfate biosynthesis), proteins involved in
hyaluronan synthesis/binding and inhibitors of NF-kappaB signaling
were among the proteins that were upregulated by miR-140. The
remaining proteins were mainly associated with cell cycle and
metabolism.
Conclusions: Addition of low levels of IL1B to cultures of ACs or SFs
constitute useful in vitro models for the pathogenesis of OA. In this
study we show that microRNA-140 protects against OA by inhibiting
key inﬂammatory molecules and stimulating synthesis of important
cartilage molecules. Delivery of microRNA-140 into OA joints may
represent a viable treatment strategy.
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MICRORNA-455 TARGETS SIRT1
T.E. Swingler y, Y. Wormstone y, M. Lott y, M. Barter z, D. Young z,
I.M. Clark y. yUniv. of East Anglia, Norwich, United Kingdom; zUniv. of
Newcastle, Newcastle, United Kingdom
Purpose: MicroRNAs (miRNAs) have emerged as a new class of gene
expression regulators that are important in both normal cartilage
physiology and pathology. MicroRNAs are 20-24 nucleotide non-
coding RNA molecules that post-transcriptionally regulate gene
expression. A single miRNA can regulate multiple mRNAs via binding
to sequences in the 30UTR either promoting mRNA decay or repres-
sing translation. We have previously identiﬁed several microRNAs
that are regulated during chondrogenesis and in osteoarthritic car-
tilage, including microRNA-455, a key Sox9-responsive microRNA.
Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A276The aim of this study was to elucidate further the role of miR-455 in
cartilage and OA by identifying direct targets of miR-455 in chon-
drocytes. In this study we have shown that miR-455 directly targets a
number of genes including Sirtuin 1 (Sirt1). Sirt1 is a NADþ
dependent protein deacetylase implicated in aging and age-related
diseases, including OA. Previous studies have shown that Sirt1 pro-
motes chondrocyte survival and is down-regulated in OA cartilage.
Mice deﬁcient for Sirt1 develop premature OA like changes. Here we
show that miR-455 directly targets Sirt1 and can regulate IL-1b sig-
nalling through NFkB, potentially regulating acetylation of Sirt1 tar-
get proteins such as NFkB/p65.
Methods: To identify potential targets of miR-455 we performed whole
genome mRNA and miRNA array analysis in the ATDC5 cell model of
chondrogenesis and mRNA array in primary chondrocytes following
overexpression or inhibition of miR-455. Whole genome mRNA
microarray used the Illumina Human HT-12 v4 Expression BeadChip;
miRNA microarray used the Exiqon miRCURY LNA Array. We further
analysed the data to identify regulated genes that also contain miR-455
binding sites. The 30UTR of potential targets were cloned into pmiR-GLO
and luciferase assays performed. The kB-luc reporter plasmid was used
to examine the effect of miR-455 on IL-1b-induced NFkB signalling.
Results: Whole genome array and bioinformatics analyses have iden-
tiﬁed a number of potential targets of miR-455, including Sirt1. Sirt1
mRNA is regulated across chondrogenesis inversely ot miR-455. Sirt1
mRNA levels decrease when miR-455 is overexpressed and increase
when miR-455 is inhibited. Sirt1 also contains a number of miR-455
binding sites. Luciferase assays conﬁrmed that Sirt1 is a direct target of
miR-455. A protein substrate of Sirt1 is NFkB/p65. We therefore used an
NFkB -responsive reporter to examine the effect of miR-455 on IL-1b
signalling through this pathway. Both miR-455 and a Sirtuin inhibitor,
nicotinamide, decreased IL1-b signalling. We are currently looking at
the effect of miR-455 on the acetylation of Sirt1 target proteins.
Conclusions: We have used bioinformatic analyses of mRNA/miRNA
expression datasets to identify a number of genes that are direct targets
of miR-455, including Sirt1. We have validated Sirt1 as a miR-455 target.
We have also shown that miR-455 can regulate IL1 signalling through
NFkB which is potentially due to altered acetylation of Sirt1 substrates,
including p65. This represents an important control mechanism for
Sirt1, a factor implicated in osteoarthritis.
OA: Ligament/Meniscus/Tendon/Muscle
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DISRUPTIVE PATHOLOGY RATHER THAN DEGENERATIVE OR
DISCRETE TEAR ARE ASSOCIATED WITH INCREASING BONE
MARROW LESION VOLUME AND A PROXY FOR TOTAL KNEE
ARTHROPLASTY: LONGITUDINAL ANALYSIS FROM THE
OSTEOARTHRITIS INITIATIVE
B. Eathakkattu Antony y,z, J. Driban y, L.L. Price y, G.H. Lo x, R.J. Ward y,
M.C. Nevitt k, L. John k, C.B. Eaton ¶, C. Ding z, T.E. McAlindon y. y Tufts
Med. Ctr., Boston, MA, USA; zMenzies Res. Inst. Tasmania, Hobart,
Australia; xMichael E. DeBakey VA Med. Ctr. and Baylor Coll. of Med.,
Houston, TX, USA; kUniv. of California at San Francisco, San Francisco,
CA, USA; ¶Brown Univ. Sch. of Med., Providence, RI, USA
Purpose: Meniscal pathology is associated with osteoarthritis (OA)
progression including increased bone marrow lesions (BMLs). How-
ever, no study has accounted for the different types of meniscal
pathology and its association with BMLs or total knee arthroplasty
(TKA). The aim of this study was to explore the association of dif-
ferent types of knee meniscal pathology with BML volume, change in
BML volume over 2 years, and a proxy for TKA according to a
modiﬁed Escobar algorithm.
Methods: We selected a convenience sample of the Osteoarthritis Ini-
tiative (OAI) who had symptomatic knee OA and complete data for the
OAI Bone Ancillary Project. The right knee was selected as the index
knee unless there was a contraindication for magnetic resonance (MR)
imaging. A single experienced fellowship trained musculoskeletal
radiologist reviewed the 24-month OAI MR images for meniscal path-
ology by location (i.e., anterior, body, and posterior horn) within the
medial and lateral menisci using a modiﬁed International Society of
Arthroscopy, Knee Surgery, and Orthopaedic Sports Medicine (ISAKOS)
meniscal tear classiﬁcation system. For analyses, we reclassiﬁed the 10
original ISAKOS categories into 5 categories: normal, degenerative sig-
nal, morphological deformity, any tear (i.e., horizontal, horizontal ﬂap,vertical-longitudinal, radial, radial-longitudinal, complex tear), and
maceration. Total number of regions affected by meniscal pathology (0-
6) was calculated by counting the number of regions in medial and
lateral menisci that had pathologic ﬁndings. BML volume assessment
was performed using a semi-automated segmentation method at 24
and 48 month visits. A CART regression was performed to identify the
meaningful abnormal BML volume cut-off value (1cm3) using medial
joint space narrowing progression as outcome. We categorized the 24-
month BML volume into 3 categories: 1) no meaningful BML volume (<
1cm3), 2) >¼ 1 cm3 and below median value (2.15cm3) and 3) above
median value of meaningful BML volume. The change in BML volume
was categorized to 4 groups: 1) no meaningful BML volume (<1cm3) at
both time points, 2) lowest quartile of meaningful BML volume change
(BML volume >¼ 1.00 cm3 at both times& BML volume change <¼-0.75
cm3), 3) middle 2 quartile of the BML volume change (BML volume >¼
1.00 cm3 at both times& BML volume change>-0.75 cm3&<¼1.00 cm3),
4) highest quartile of the BML volume change (BML volume >¼ 1.00 cm3
at both times & BML volume change >1.00 cm3). We categorized the
proxy for TKA into appropriate and non-appropriate based on the
algorithm developed by Escobar et al and adapted to OAI by Riddle et al.
To replicate prior studies, we explored whether the presence or absence
of any meniscal pathology was associated with BMLs and a proxy for
TKA. Logistic regression (ordinal for Table 1 and binary for Table 2) was
performed to determine the association of baseline meniscal pathology
with BML volume, change in BML volume and a proxy for TKA. All
models were adjusted for age, sex and body mass index (BMI).
Results: 400 participants were included in the analysis with mean age of
63 (9.2) years, 53%male, BMI29.6 (4.6) kg/m2, 71%KLgrade>¼2, andwith
86% having any type of meniscal pathology. Tables below provide the
associations betweenmeniscal pathology and BML volume (Table 1), BML
volume change (Table 1) and proxy for TKA (Table 2). There was a sig-
niﬁcant association between any meniscal pathology with BML volume
(OR:3.87) and change in BML volume (OR:2.32) but not with proxy for
TKA. Having more number of regions of the menisci affected with path-
ology was associated with greater BML volume, change in BML volume,
andproxy for TKA than thosewith a normalmeniscus. Among the types of
meniscal pathology, only morphological deformity and maceration were
associated with BML volume, change in BML volume, and proxy for TKA.
Removing surgery or injury cases did not change our results.
Conclusions: Among the ﬁve categories of meniscal pathologies, dis-
ruptive pathology rather than degenerative or discrete tear was asso-
ciated with structural changes and a later clinical state that is proxy for
TKA. This suggests that pathologies that impair normal load distribution
properties of meniscus can cause damage to the knee joint.
